Amgen preparing for Phase III of rilotumumab in gastric/gastroesophageal cancer
This article was originally published in Scrip
Executive Summary
Amgen is to begin a Phase III trial of its investigational fully human monoclonal antibody, rilotumumab (AMG 102) later this year, based on an exploratory biomarker analysis –marking another advance with personalised medicine in the field of gastric and gastroesophageal oncology.